LUCD Reports Results
Lucid Diagnostics (NASDAQ:LUCD), a diagnostics company focused on non-invasive detection of esophageal precancer and cancer, released its second quarter 2025 earnings results on August 13, 2025. GAAP revenue was $1.2 million, Non-GAAP EPS was $(0.10), beating analyst estimates, and a better-than-expected non-GAAP EPS loss of $(0.10), outperforming the estimated non-GAAP EPS of $(0.11). Net loss attributable to common stockholders (GAAP) was $7.9 million, an improvement from the $(11.01 million) GAAP net loss attributable to common stockholders in Q2 2024. The quarter was marked by ongoing advances in reimbursement and an improved cash position. Overall, the results show steady commercial progress, but also highlight persistent operating losses and continued focus on expanding insurance coverage.
Source: Analyst estimates for the quarter provided by FactSet.
Lucid Diagnostics develops and commercializes non-invasive technologies for diagnosing esophageal precancer and cancer. Its main products, EsoGuard and EsoCheck, offer a DNA-based test and a swallowable balloon cell collection device, respectively. These tools address the need for earlier and simpler detection, aiming at high-risk populations in the United States.
Source Fool.com
